Solidité financière et newsflow à court terme - ACHAT - OC 91€ (vs 93€)
La société a publié hier après Bourse des résultats semestriels sans grande surprise. Malgré une hausse significative des coûts de R&D sur la période du fait des différentes avancées cliniques (+70%), ADOCIA présente toujours une trésorerie solide à 60,9m€ (cash burn de 11m€ sur la période). La société revient également sur les principaux résultats cliniques à court terme : (i) BioChaperone PDGF-BB en phase III dans l’ulcère du pied chez le diabétique au T3, (ii) Hinsbet en phase Ib également lors de ce T3 et (iii) les résultats de BC Lispro en phase Ib lors de ce T4. Nous maintenons notre recommandation à ACHAT en ajustant notre objectif de cours de 93€ à 91€.ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.